Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO Sells $1,382,400.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John E. Kao sold 90,000 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $15.36, for a total value of $1,382,400.00. Following the transaction, the chief executive officer now directly owns 2,093,100 shares of the company’s stock, valued at approximately $32,150,016. This trade represents a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Alignment Healthcare Trading Down 1.3 %

NASDAQ ALHC traded down $0.21 during trading on Thursday, hitting $15.50. The company had a trading volume of 1,216,078 shares, compared to its average volume of 2,088,706. The company’s fifty day moving average is $14.22 and its 200-day moving average is $12.34. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The company has a market cap of $2.97 billion, a price-to-earnings ratio of -20.13 and a beta of 1.49. Alignment Healthcare, Inc. has a one year low of $4.46 and a one year high of $16.25.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALHC. R Squared Ltd purchased a new stake in Alignment Healthcare in the fourth quarter worth $55,000. RiverPark Advisors LLC bought a new position in shares of Alignment Healthcare during the fourth quarter valued at approximately $106,000. Tower Research Capital LLC TRC raised its stake in Alignment Healthcare by 146.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company’s stock valued at $119,000 after buying an additional 6,286 shares during the last quarter. Ballentine Partners LLC purchased a new stake in Alignment Healthcare during the 4th quarter valued at about $121,000. Finally, Aigen Investment Management LP bought a new stake in shares of Alignment Healthcare during the fourth quarter valued at approximately $129,000. Institutional investors own 86.19% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Alignment Healthcare in a research note on Friday, February 28th. Barclays raised their price target on Alignment Healthcare from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Friday, February 28th. JPMorgan Chase & Co. lifted their price objective on shares of Alignment Healthcare from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Thursday, March 6th. Stephens restated an “overweight” rating and issued a $17.00 target price on shares of Alignment Healthcare in a research report on Monday, February 24th. Finally, Bank of America upped their price target on shares of Alignment Healthcare from $15.50 to $18.50 and gave the company a “buy” rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.